Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of injectable HRS9432 for candidemia and other invasive candidiasis
CTR20234199Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9432 in candidemia, invasive candidiasis, sponsored by Fujian Shengdi Pharmaceuticals. Started Apr 2024; status: completed.
02
Drugs
HRS9432
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on CTR20234199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234199.